Life expectancy of patients undergoing surgical aortic valve replacement compared with that of the general population.


Journal

Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 13 08 2019
revised: 08 10 2019
accepted: 14 10 2019
pubmed: 20 11 2019
medline: 6 10 2020
entrez: 20 11 2019
Statut: ppublish

Résumé

Surgical aortic valve replacement (SAVR) changes the natural history of severe aortic stenosis. However, whether the life expectancy of patients with severe aortic stenosis undergoing this surgical procedure is fully restored is unknown. The objective of this study was to assess if the life expectancy of patients aged >75 years is fully restored after undergoing surgery for severe aortic stenosis. We compared long-term survival of a group of patients aged >75 years, who underwent SAVR at our institution with the long-term survival of the general population. We matched each patient with 100 simulated individuals (control group) of the same age, sex and geographical region who died as indicated by the National Institute of Statistics. We compared survival curves and calculated hazard ratio (HR) or incidence rate ratio. Statistical significance existed if confidence intervals (CIs) did not overlap or did not include the value 1, as appropriate. Average life expectancy of surgical patients who survived the postoperative period was 90.91 months (95% CI 82.99-97.22), compared to 92.94 months (95% CI 92.39-93.55) in the control group. One-, 5- and 8-year survival rates for SAVR patients who were discharged from the hospital were 94.9% (95% CI 92.74-96.43%), 71.66% (95% CI 67.37-75.5%) and 44.48% (95% CI 38.14-50.61%), respectively, compared to that of the general population: 95.8% (95% CI 95.64-95.95%), 70.64% (95% CI 70.28%-71%) and 47.91% (95% CI 47.52-48.31%), respectively (HR 1.07, 95% CI 0.94-1.22). For patients over the age of 75 years who underwent SAVR and survived the postoperative period, life expectancy and survival rates were similar to that of the general population.

Identifiants

pubmed: 31740947
pii: 5628298
doi: 10.1093/icvts/ivz268
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

394-399

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Daniel Hernandez-Vaquero (D)

Cardiac Surgery Department, Central University Hospital of Asturias, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.

Rocio Diaz (R)

Cardiac Surgery Department, Central University Hospital of Asturias, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.

Alberto Alperi (A)

Department of Cardiology, Central University Hospital of Asturias, Oviedo, Spain.

Marcel G Almendarez (MG)

Department of Cardiology, Central University Hospital of Asturias, Oviedo, Spain.

Alain Escalera (A)

Cardiac Surgery Department, Central University Hospital of Asturias, Oviedo, Spain.

Hector Cubero-Gallego (H)

Department of Cardiology, Central University Hospital of Asturias, Oviedo, Spain.

Pablo Avanzas (P)

Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
Department of Cardiology, Central University Hospital of Asturias, Oviedo, Spain.
University of Oviedo, Oviedo, Spain.

Cesar Moris (C)

Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
Department of Cardiology, Central University Hospital of Asturias, Oviedo, Spain.
University of Oviedo, Oviedo, Spain.

Isaac Pascual (I)

Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
Department of Cardiology, Central University Hospital of Asturias, Oviedo, Spain.
University of Oviedo, Oviedo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH